ACADEMIC APPOINTMENTS, PROFESSIONAL POSITIONS, AND HONORS
Positions and Employment:
Teaching Assistant, Department of Chemistry, National Taiwan University, Taipei, Taiwan, 1967-1968
Research Scientist, Department of Psychiatry, Psychiatry Research Unit, University of Saskatchewan, Saskatoon, Canada, 1975-1977
Professional Research Associate, Department of Physiology, College of Medicine, University of Saskatchewan, Saskatoon, Canada, 1977-1982
Research Associate, Department of Physiology, School of Medicine, Wayne State University, Detroit, Michigan U.S.A., 1982-1984
Research Scientist, Clinical Pharmacology and Neurology Programs, Clinical Institute, Addiction Research Foundation of Ontario, Toronto, Canada, 1984-1986
Research Associate, Department of Pharmacology, University of Toronto, Canada, 1987-1988
Scientist III, Addiction Research Foundation, Toronto, Canada, 1995-1998
Assistant Professor (Pharmacology), University of Toronto, Toronto, Canada, 1989-1998
Associate (Neuroscience), Playfair Neuroscience Unit, Toronto Hospitals, 1989-1998
Instructor, Department of Pharmacology, University of Colorado Health Sciences Center, Denver, Colorado, 1998-2003
Instructor, Department of Psychiatry, University of Colorado Health Sciences Center, Denver, Colorado, 2003-2007
Assistant Professor, Department of Psychiatry, University of Colorado Denver, School of Medicine, Aurora, Colorado, 2007-
Other Experience and Professional Memberships:
Post-doctoral Fellow, Psychiatric Research Unit, Department of Psychiatry, University of Saskatchewan, Saskatoon, Canada, 1972-74
Visiting Scientist, Arbeitsgruppe Neurochemie, Max Planck Institut für Experimentelle Medizin, Göttingen, West Germany, 1974
Member, Research Society on Alcoholism, 1998-
Human physiology course (Physiology 212), 1978-82
Tutor for Medical Students (Physiology 303)
Medical Physiology, 1984-85
Neuroscience 1444, Neuroscience 444, Neuroscience Program, 1988-95
Biochemical Pharmacology (Pharmacology of Ion Channels), 1988-89
Fundamental Concepts of Drug Abuse: Pharmacology of Drug Abuse, 1988-92
Graduate Pharmacology, Cellular Messengers in Signal Transduction, 1989-93
Experimental Pharmacology (Pharmacology 471 & 1009), 1989-97
Mentor: Pharmacology 472, 1989-97
Course Director: Human Physiology, 2003
Guest lecturer on drug abuse and health, 2006
Guest lecturer on drug abuse and health, 2007
SCHOLARSHIPS AND PUBLICATIONS
Selected Peer-Reviewed Publications (out of 135):
“Animal Models of Drug Addiction” Neuromethods vol. 24, A.A. Boulton, G.B. Baker and P.H. Wu (eds), Humana Press, Clifton, New Jersey (1992).
Khanna JM, Mihic SJ, Weiner J, Shah G, Wu PH, and Kalant H, Differential inhibition by NMDA antagonists of rapid tolerance to, and cross tolerance between, ethanol and chlordiazepoxide, Brain Res. 574: 251-258 (1992).
Mihic SJ, Kalant H, Liu JF, and Wu PH, GABA-receptor/chloride-channel complex in tolerance to ethanol and cross tolerance to diazepam and pentobarbital, J. Pharmacol. Exp. Ther. 261: 108-113 (1992).
Khanna JM, Shah G, Weiner J, Wu PH, and Kalant H. Effect of NMDA receptor antagonists on rapid tolerance to ethanol. Eur. J. Pharmacol. 230: 23-31 (1993).
Wu PH, Mihic SJ, Liu JF, Lê AD and Kalant H. Blockade of chronic tolerance to ethanol by the NMDA antagonist, (+) MK-801. Eur. J. Pharmacol. 231: 157-164 (1993).
Nguyen T, Marchese A, Kennedy JL, Petronis A, Peroutka SJ, Wu PH and O'Dowd BF. An Alu sequence interupts a human 5-hydroxytryptamine 1D receptor pseudogene. Gene 124: 295-301 (1993).
Murphy MP, Wu PH, Milgram NW and Ivy GO. Monoamine oxidase inhibition by l-Deprenyl depends on both sex and route of administration in the rat. Neurochem. Res. 18: 1299-1304 (1993).
Milgram NW, Ivy GO, Head E, Murphy MP, Wu PH, Ruehl WW, Yu PH, Durden DA, Davis BA, Paterson IA and Boulton AA. The effect of l-Deprenyl on behavior, cognitive function, and biogenic amines in the dog. Neurochem. Res. 18: 1211-1219 (1993).
Carlen PL, Gurevich N, Zhang L, Wu PH, Reynaud D, Pace-Asciak CR. Formation and electrophysiological actions of the arachidonic acid metabolites, hepoxilins, at nanomolar concentrations in rat hippocampal slices. Neurosci. J. 58: 493-502 (1994).
Carrillo MC, Ivy GO, Milgram NW, Head E, Wu P, and Kitani K. (-)Deprenyl increases activities of superoxide dismutase (SOD) in striatum of dog brain. Life Sci. 54: 1483-1489 (1994).
Ren W-Z, Ng GYK, Wang RX, Wu PH, O'Dowd BF, Osmond DH, George SR, Liew CC. The identification of NP25: a noval protein that is differentially expressed by neuronal subpopulations. Mol. Brain Res. 22: 173-185 (1994).
Wu PH, Liu J-F, Lança AJ, Kalant H. Selective involvement of central 5-HT2 receptors in the maintenance of tolerance to ethanol by arginine-8-vasopressin. J. Pharmacol. Exp. Ther. 270: 802-808 (1994).
Milgram NW, Ivy GO, Murphy MP, Head E, Wu PH, Ruehl B, Yu PH, Durden DA, Davis BA, Boulton AA. Effects of chronic oral admin of deprenyl in the dog. Pharmacol. Biochem. Behav. 51: 421-428 (1995).
Paterson IA, Davis BA, Durden DA, Juorio AV, Yu PH, Ivy G, Milgram W, Mendonca A, Wu P, Boulton AA. Inhibition of MAO-B by (-)deprenyl alters dopamine metabolism in the Macaque (Macaca Facicularis) brain. Neurochem. Res. in press (1995).
Wu PH, Lança AJ, Liu JF, Man CF, Kalant H. Peripheral injection of arginine8-vasopressin increases Fos in specific brain areas. Eur. J. Pharmacol. 281: 263-269 (1995).
Wu PH, Liu J-F, Kalant H. Development of alcohol tolerance in the rat after single exposure to combined treatment with arginine-8-vasopressin and ethanol. J. Pharmacol. Exp. Ther. 276: 1283-1291 (1996).
Rafi-Tari S, Kalant H, Liu J-F, Silver I, Wu PH. Dizocilpine prevents the development of tolerance to ethanol- induced error on a circular maze test. Psychopharmacology 125: 23-32 (1996).
Cheung SW, Nolte H, Otton SV, Tyndale RF, Wu PH, and Sellers EM. Simultaneous determination of methamphetamine, amphetamine and their p-hydroxylated metabolites in plasma and urine. J. Chromatogr. (Biomedical application): 690: 77-87 (1997).
Lança AJ, Wu PH, Liu J-F, Jung B, Ng V, and Kalant H. Differential increase of immunoreactivity to Fos and Fos-like proteins in specific brain areas by arginine8-vasopressin and desglycinamide9-arginine8-vasopressin. Neuroscience J. 91: 1331-1341 (1999).
Chiu J, Brien JF, Wu P, Eubanks JM, Zhang L, Reynolds JN. Chronic ethanol exposure alters MK-801 binding sites in the cerebral cortex of the near-term fetal guinea pig. Alcohol 17: 215-221(1999).
Yoshimura M, Wu PH, Hoffman PL, Tabakoff B. Overexpression of type 7 adenylyl cyclase in mouse brain enhances acute and chronic actions of morphine. Mol. Pharmacol. 58: 1011 - 1016 (2000).
Wu PH, Tabakoff B, Szabó G, Hoffman PL. Chronic ethanol exposure results in increased acute functional tolerance in selected lines of HAFT and LAFT mice. Psychopharmacology 155: 405-412 (2001).
Proctor WR, Wu PH, Bennett B and Johnson TE. Hippocampal GABAA IPSCs in ILS Congenic lines of mice show differential sensitivities to ethanol. Alcoholism: Clin Exp Res. 28: 1277-1283. (2004).
Wu PH, Poelchen W and Proctor WR. Differential GABAB receptor modulation of ethanol effects on GABAA synaptic activity in hippocampal CA1 neurons. J. Pharmacol. Exp. Ther, 312, 1082-1089 (2005).
Proctor WR, Lihong Diao, Freund RK, Browning MD, Wu PH. Synaptic GABAergic and glutamatergic mechanisms underlying alcohol sensitivity in mouse hippocampal neurons. J. Physiol 575: 145-159 (2006).
Xu J, Kurup P, Zhang Y, Goebel-Goody SM, Wu PH, Hawasli AH, Baum ML, Bibb JA, Lombroso PJ. Extrasynaptic NMDA receptors couple preferentially to excitotoxicity via calpain-mediated cleavage of STEP. J Neurosci 29:9330-9343 (2009).
Grants and Contracts:
R21 AA - Proctor (PI), 9/01/08 – 8/31/10
Chronic nicotine modulates ethanol effects on GABAergic and glutamatergic transmission.
The goal of this project is to investigate the acute and chronic interaction between nicotine and alcohol on brain GABAergic and glutamatergic neurotransmission in C3H mice. Evidence indicates that alcohol can modify functional nicotinic receptor activity leading to altered GABAergic and glutamatergic transmission.
R01 AA014691-01 - Browning (PI), 7/01/05 – 6/30/10
The goal is to study the molecular mechanisms that underlie the differences in ethanol sensitivity of the GABAAR and NMDAR in ILS and ISS mice, two strain of mice that are high-sensitive (ILS) and low-sensitive to the hypnotic effects of ethanol.
NIH/NIMH Conte Center Grant - Freedman (PI), 8/01/09 – 7/31/14
Basic to Clinical Molecular Neurobiology of Nicotinic Receptors in Schizophrenia.
Project 4: Mouse Molecular and Neurobiological models
The goal of Project 4 is to investigates the DBA/2 animal model in three ways: 1) molecular identification of the DNA mechanisms responsible for abnormal expression of the DBA/2 Chrna7 for comparison with abnormalities in CHRNA7 in schizophrenia, 2) an analysis at the single neuron level of the effects of the DBA/2 Chrna7 on the development of cholinergic, GABAergic, and glutamatergic neurotransmission in the hippocampus and 3) a pharmacological investigation of the effects of a7nAChR agonists, including choline, on the development of auditory gating function, as a translational model for infant choline intervention.